| Name | 3-TYP |
| Description | 3-TYP (3-(1H-1,2,3-triazol-4-yl) pyridine) is a selective SIRT3 inhibitor. |
| Cell Research | Cell viability is analyzed using Cell Counting Kit-8. 1×104 cells are inoculated into 96-well plates. After being treated, 90 μL of medium and 10 μL of CCK-8 solution are added to each well. The cells are then incubated at 37°C for 2 h. After incubation, the absorption at 450 nm is measured using an Infinite? M200 Microplate Reader. The results are expressed as a percentage of the control. The cell death is also evaluated using the trypan blue assay. HepG2 cells are plated in the 6-well plates (5×105 cells per well) and incubated for 24 h. After being treated with Cd or melatonin, the cells are detached with 300 μL trypsin-EDTA solution. The mixture of detached cells is centrifugated at 300 g for 5 min. Then, the residue is combined with 800 μL trypan blue solution and dispersed. After 3 min staining, cells are counted using an automated cell counter. The dead cells are stained with the blue color. Cell mortality (%) is expressed as percentage of the dead cell number/the total cell number. |
| Animal Research | 3-TYP is formulated in 1% ethanol.Male C57BL/6 mice are anesthetized with 2% isoflurane, and myocardial ischemia is produced by temporarily exteriorizing the heart via a left thoracic incision and placing a 6-0 silk suture slipknot around the left anterior descending coronary artery. After 30 minutes of myocardial ischemia, the slipknot is released, and the myocardium is reperfused for 3 hour (for western blot analysis and oxidative stress measurement) or 24 hour (for cardiac function, apoptotic index and infarct size determination). Sham-operated mice undergo the same surgical procedures except the suture placed under the left coronary artery is not tied. Ten minutes before reperfusion, mice are randomized to receive either vehicle (1% ethanol) or melatonin (20 mg/kg) by intraperitoneal injection. C57BL/6 mice are randomly divided into the following groups: (i) Sham group: mice underwent the sham operation and are treated with vehicle (1% ethanol); (ii) Mel group: mice are treated with melatonin (20 mg/kg via intraperitoneal injection); (iii) IR+V group: mice underwent the MI/R operation and are treated with vehicle (1% ethanol); (iv) IR+Mel group: mice underwent the MI/R operation and are treated with melatonin (20 mg/kg via intraperitoneal injection 10 minutes before reperfusion); (v) IR+Mel+3-TYP group: mice are pretreated with 3-TYP (3-TYP is intraperitoneally injected at a dose of 50 mg/kg every 2 days for a total of three doses prior to the MI/R surgery), subjected to the MI/R operation, and treated with melatonin (20 mg/kg via intraperitoneal injection 10 minutes before reperfusion); and (vi) IR+3-TYP group: mice are pretreated with 3-TYP and then subjected to the MI/R operation. |
| In vitro | 3-TYP significantly attenuates melatonin-induced increases in deacetylated-SOD2 expression and SOD2 activity in HepG2 cells exposed to Cd. 3-TYP inhibits melatonin-enhanced SIRT3 activity while not affecting SIRT3 protein expression. 3-TYP pretreatment reverses the protective effects of melatonin on cadmium (Cd)-induced mitochondrial-derived O2•− production and autophagic cell death. |
| In vivo | 3-TYP significantly reduces SIRT3 activity and increases SOD2 acetylation compared to the control group while not affecting SIRT3 expression. It undermines the cardioprotective effects of melatonin by reducing left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) and increases infarct size, serum lactate dehydrogenase (LDH) levels, and the apoptotic ratio after 24 hours of reperfusion, relative to the IR+Mel group. However, at a dose of 50 mg/kg, intraperitoneally (i.p.), 3-TYP shows no significant effect on LVEF, LVFS, infarct size, serum LDH levels, apoptosis, and oxidative stress compared to the Sham group. Additionally, 3-TYP does not significantly affect the expression levels of gp91phox, Nrf2, NQO 1, Bax, Bcl-2, Caspase-3, and cleaved Caspase-3 compared to the Sham group. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (34.21 mM), Sonication is recommended.
H2O : 5 mg/mL (34.21 mM), Sonication is recommended.
Ethanol : 28 mg/mL (191.58 mM), Sonication is recommended.
DMSO : 231 mg/mL (1580.57 mM), Sonication is recommended.
|
| Keywords | Sirtuin | SIRT3 | SIRT2 | SIRT1 | Inhibitor | inhibit | 3-TYP | 3TYP | 3 TYP |
| Inhibitors Related | Selisistat | Dihydrocoumarin | Nicotinamide riboside chloride | Resveratrol | SRT 2104 | Nicotinamide riboside | Indoximod | Epacadostat | Fisetin | β-Lapachone | SIRT5 inhibitor 8 | Nicotinamide |
| Related Compound Libraries | Histone Modification Compound Library | Reprogramming Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Epigenetics Compound Library | Glutamine Metabolism Compound Library | Chromatin Modification Compound Library | Antioxidant Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
United States
